Gilead Sciences, Inc. (NASDAQ: GILD) has announced plans to present research from more than 50 studies at the International Congress on Drug Therapy in HIV Infection, highlighting the expanding clinical evidence supporting long-acting HIV prevention, simplified treatment regimens and investigational approaches targeting persistent viral infection. Announced on November 2, 2026, the programme will be presented at HIV Glasgow from November 8 to 11 and includes new analyses from Phase 3 trials of once-weekly oral treatment, Phase 2 research into twice-yearly pre-exposure prophylaxis and early studies of potential long-acting injectable combinations.
The presentations will cover Gilead’s established commercial medicines and investigational pipeline, including Biktarvy, the recently US-approved bictegravir/lenacapavir combination Bixlenvo, the twice-yearly prevention medicine lenacapavir and a once-weekly oral combination being developed with Merck & Co., Inc. The company will also discuss an investigational integrase inhibitor, GS-3242, and a bispecific antibody designed to engage immune cells against HIV-infected cells.
The scientific programme comes as Gilead’s HIV business continues to deliver strong commercial growth. Third-quarter 2026 HIV sales increased 18% year on year to approximately $6.2 billion, while Biktarvy generated around $4.1 billion. However, the conference announcement primarily previews forthcoming presentations rather than disclosing new numerical results, and several pipeline candidates remain investigational despite encouraging earlier findings.
Why is Gilead placing long-acting HIV treatment and prevention at the centre of Glasgow 2026?
HIV management has changed substantially as combination antiretroviral therapy has enabled many people living with HIV to achieve durable viral suppression. Effective treatment can prevent disease progression and, when viral suppression is sustained, eliminate the risk of sexual transmission under the principle known as Undetectable equals Untransmittable. Nevertheless, lifelong treatment introduces challenges involving adherence, medication access, side effects and individual preferences.
Gilead’s long-acting strategy aims to provide alternatives to conventional daily oral regimens. Its development portfolio includes once-weekly tablets and potential twice-yearly injectable treatment combinations, alongside an already approved twice-yearly prevention option. The objective is not simply to reduce the number of doses but to expand the range of regimens available to people with different clinical and practical needs.
The company has identified lenacapavir as a central component of this strategy. The HIV capsid inhibitor interferes with multiple stages of the viral lifecycle and has a mechanism distinct from established antiretroviral drug classes. Its pharmacological characteristics allow the development of combinations using different dosing schedules.
However, a less frequent regimen must still maintain effective viral suppression or prevention. Long dosing intervals also create particular considerations involving resistance, missed appointments and management of adverse events. The clinical value of extended dosing therefore depends on effectiveness and safety as well as convenience.
Jared Baeten, senior vice-president and head of clinical development for Gilead’s virology therapeutic area, has described the conference programme as reflecting the company’s continuing effort to expand person-centred HIV care. The forthcoming evidence will help determine how long-acting options fit different treatment and prevention populations.
What will the PURPOSE 5 study reveal about persistence with twice-yearly lenacapavir PrEP?
PURPOSE 5 is a Phase 2 study investigating twice-yearly injectable lenacapavir as HIV pre-exposure prophylaxis among individuals in the United Kingdom and France who had not previously engaged with daily oral PrEP. The study compares the injectable approach with daily oral emtricitabine/tenofovir disoproxil fumarate, commonly associated with Truvada.
At Glasgow, researchers are scheduled to present one-year findings concerning persistence and safety. Persistence refers to whether participants continue using their assigned prevention option over the observation period. It differs from drug efficacy, because a treatment can be highly effective when administered correctly but provide limited protection if patients do not continue using it.
The comparison is relevant because daily medication can be difficult to maintain for some individuals. A twice-yearly injection may reduce daily pill-taking requirements, potentially improving acceptability for certain populations. However, injections require scheduled healthcare contact, and missed dosing appointments can create their own challenges.
Lenacapavir is already authorised for HIV prevention in the United States, European Union and other markets, with different brand names used across jurisdictions. Yeztugo is the US prevention brand, while Yeytuo is used in Europe. The Glasgow study therefore investigates persistence and safety within a particular population rather than establishing the medicine’s first regulatory approval.
The company has not disclosed the new one-year persistence percentages in its November 2 announcement. The findings should therefore be described as scheduled results, not as confirmed evidence of improved adherence in the PURPOSE 5 population.
How important are the once-weekly ISLEND Phase 3 results for future HIV treatment?
Gilead and Merck are jointly developing an investigational once-weekly oral single-tablet regimen combining islatravir 2 mg with lenacapavir 300 mg. Islatravir is a nucleoside analogue with mechanisms including reverse transcriptase translocation inhibition, while lenacapavir targets the HIV capsid. The combination is designed to maintain viral suppression using two agents with complementary antiviral activity.
The Phase 3 ISLEND-1 and ISLEND-2 studies have already achieved their primary efficacy endpoints. In June 2026, the companies reported that once-weekly treatment was statistically non-inferior to the relevant daily comparator regimens at week 48. This is an established topline result, not a new outcome being announced for the first time at Glasgow.
ISLEND-1 evaluated patients who had maintained viral suppression on Biktarvy, comparing a switch to the once-weekly combination with continuing daily treatment. ISLEND-2 examined patients switching from a wider range of standard antiretroviral regimens. The trials were designed to assess whether the investigational treatment could maintain viral suppression without an unacceptable increase in virological failure.
The Glasgow presentations will add analyses across demographic and clinical subgroups, together with treatment preference and quality-of-life findings. These are important because overall non-inferiority does not automatically establish equivalent performance in every patient subgroup. A regimen may also be effective but less acceptable to certain patients because of scheduling or tolerability considerations.
The combination remains investigational and is not approved by any regulatory authority. The next major steps involve complete analysis of the Phase 3 evidence and regulatory submissions. Positive topline results provide a foundation but do not guarantee approval or establish a commercial launch date.
Why does patient preference matter when switching from daily to once-weekly HIV treatment?
Once-weekly dosing can potentially reduce the number of medication-taking occasions from seven per week to one. For individuals who prefer fewer treatment reminders, this may be attractive. However, dosing frequency is only one component of treatment satisfaction, and some people may prefer the familiarity and routine of established daily medicines.
The ISLEND-2 programme includes research examining the experiences of participants and healthcare providers who switched to the weekly combination. Investigators are also evaluating quality of life and treatment preferences at week 48. These outcomes could help determine whether reduced dosing frequency translates into a meaningful improvement in the treatment experience.
An important practical consideration is the consequence of missing a dose. With a daily regimen, patients may have established routines for managing missed medication, while longer-acting treatment requires clear guidance about dosing interruptions and restarting therapy. The pharmacological characteristics of a weekly combination must support an appropriate safety margin.
Patient preference findings also need to be interpreted in the context of trial design. Participants volunteering for a clinical study of a novel regimen may have greater interest in alternative dosing than the broader treatment population. Open-label assessments can also be influenced by expectations regarding the new medicine.
Ultimately, successful long-acting treatment must combine durable viral suppression with acceptable tolerability and practical administration. A lower pill burden may increase convenience, but it should not be treated as evidence of better long-term adherence until supported by clinical or real-world data.
What does the approval of Bixlenvo mean for Gilead’s existing HIV treatment portfolio?
In August 2026, the FDA approved Bixlenvo, a once-daily single-tablet combination of bictegravir 75 mg and lenacapavir 50 mg, for selected virologically suppressed adults with HIV. The treatment combines an integrase inhibitor with a capsid inhibitor, providing an option for patients who may previously have required more complex regimens.
Bixlenvo requires a two-day initiation regimen involving additional lenacapavir before patients continue with the once-daily tablet. This administration detail is important because the approved treatment is not simply initiated as a standalone daily pill without the prescribed loading approach. Its indicated use also differs from that of therapies designed for patients beginning HIV treatment without prior viral suppression.
At HIV Glasgow, Gilead will present additional results from the ARTISTRY clinical programme supporting the combination. These include analyses of patients with pre-existing resistance-associated mutations and the occurrence of viraemic events after switching treatment. Such findings could help clarify how the regimen performs in clinically complex populations.
The company is also evaluating Bixlenvo through real-world care as commercial experience accumulates. However, regulatory status differs between jurisdictions. The bictegravir/lenacapavir combination is approved in the United States but remains investigational in the European Union and United Kingdom.
The commercial opportunity lies partly in simplifying therapy for patients who cannot use conventional single-tablet regimens. Nevertheless, a switch must be supported by resistance history, previous treatment experience and other clinical factors. The approved indication does not mean Bixlenvo is suitable for every person living with HIV.
Why is Gilead continuing to study Biktarvy in patients with multiple health conditions?
Biktarvy remains a cornerstone of Gilead’s HIV business and is widely used for treatment across different patient populations. The combination contains bictegravir, emtricitabine and tenofovir alafenamide. Its established efficacy and commercial presence provide a benchmark against which newer regimens must demonstrate appropriate effectiveness.
The BICSTaR programme is a global observational study evaluating Biktarvy in routine clinical practice. It includes treatment-naive and treatment-experienced patients, including individuals with comorbidities that may complicate long-term HIV management. The Glasgow presentations will include analyses of treatment outcomes and patient-reported measures.
The focus on comorbidities reflects the changing demographics of people living with HIV. Effective antiretroviral treatment has improved life expectancy, increasing the importance of cardiovascular, metabolic, renal and other health conditions that may arise with ageing. Treatment choices must therefore consider drug interactions and the wider clinical needs of individual patients.
Real-world research can provide information about treatment persistence and effectiveness in populations that are not fully represented in pivotal trials. However, observational studies cannot eliminate selection bias, and their findings may be influenced by differences in patient characteristics and clinical care.
For Gilead, continuing to generate evidence for Biktarvy serves both clinical and commercial purposes. The medicine generated approximately $4.1 billion in third-quarter sales, making its competitive position central to the company’s financial outlook.
Can GS-3242 and lenacapavir establish a twice-yearly injectable treatment option?
Gilead is developing GS-3242, an investigational integrase inhibitor, as a potential component of a twice-yearly injectable HIV treatment regimen. The compound is being evaluated with lenacapavir, which already has an established role in certain approved HIV treatment and prevention applications. Combining the agents could potentially create a long-acting treatment strategy with distinct antiviral targets.
The Glasgow programme will include Phase 1b findings concerning oral GS-3242, including antiviral activity, pharmacokinetics and safety. The company is also evaluating the GS-3242/lenacapavir combination in two Phase 2 studies, PULSAR 1 and PULSAR 2. These programmes are intended to investigate whether the combination can support extended dosing intervals.
In October 2026, GS-3242 received FDA Fast Track designation. This supports development and potentially facilitates regulatory engagement, but it does not establish that the compound is effective or approved. The combination remains investigational, and its safety and efficacy have not been demonstrated sufficiently for marketing authorisation.
A twice-yearly treatment could substantially reduce the frequency of administration compared with daily medication. However, developing a long-acting combination requires careful matching of drug exposure over the dosing interval. If the components decline at different rates, periods of inadequate antiviral coverage could potentially increase resistance risk.
The future development programme must therefore evaluate pharmacokinetics, viral suppression and the management of missed or delayed injections. The clinical value will depend on maintaining reliable antiviral coverage, not merely achieving an extended dosing schedule.
What does the amtabafusp alfa programme reveal about Gilead’s ambitions beyond lifelong HIV suppression?
Gilead will also present early research involving amtabafusp alfa, formerly designated GS-8588, an investigational bispecific T-cell engager designed to target the persistent HIV reservoir. The programme examines whether immune cells can be directed towards HIV-infected cells that remain despite otherwise effective antiretroviral therapy. Its long-term objective differs from conventional treatment, which primarily suppresses viral replication.
The HIV reservoir represents a major obstacle to curing infection. Viral genetic material can persist in long-lived cells even when blood tests show sustained suppression. Stopping antiretroviral therapy in most people allows infection to rebound, demonstrating that conventional treatment does not eliminate the reservoir.
A bispecific T-cell engager attempts to connect immune effector cells with a relevant target on infected cells. In principle, this could support immune-mediated clearance of some reservoir-containing cells. However, the effectiveness and safety of such an approach depend on target expression, immune activation and the accessibility of infected cells.
The upcoming Phase 1b findings will concern immunogenicity and associated safety. They should not be described as evidence of an HIV cure, elimination of the reservoir or successful treatment interruption. No approved medicine currently provides a broadly applicable cure for HIV.
The programme demonstrates how Gilead is pursuing research beyond existing commercial antiretroviral treatments. However, its clinical development remains at an early stage, and meaningful conclusions about cure potential would require substantial additional evidence.
How do resistance and equitable access influence the long-acting HIV treatment opportunity?
Resistance remains an important consideration in HIV treatment because the virus can develop mutations that reduce susceptibility to particular medicines. Effective combination therapy aims to suppress replication sufficiently to minimise this risk. New regimens must therefore be evaluated carefully in patients with previous treatment failure or known resistance-associated mutations.
The ARTISTRY and ISLEND studies provide opportunities to investigate resistance outcomes when patients switch from established treatment. However, the suitability of any regimen depends on its authorised indication and the patient’s treatment history. A simplified dosing schedule does not remove the need for resistance-informed prescribing.
Access is equally important for prevention. Long-acting injections may address adherence challenges associated with daily PrEP, but they require diagnostic testing, clinical visits and reliable supply. Insurance arrangements, pricing and healthcare infrastructure can influence whether the medicines reach populations at greatest risk of HIV acquisition.
Gilead’s Glasgow programme includes research on barriers to PrEP, transitions from post-exposure prophylaxis and the potential public health effects of removing financial obstacles. These analyses reflect the distinction between the efficacy of a medicine and its actual impact when deployed through health systems.
A highly effective prevention product cannot achieve its full population benefit if eligible individuals cannot access it or maintain the required treatment schedule. Future progress will therefore depend on implementation strategies as well as pharmacological innovation.
What do Gilead’s latest financial results and share performance indicate about its HIV growth strategy?
Gilead reported third-quarter 2026 revenue of $8.3 billion, an increase of approximately 7% from the prior year. Product sales excluding Veklury increased 16% to $8.2 billion, supported by an 18% increase in HIV sales to approximately $6.2 billion. Biktarvy sales rose 10% to $4.1 billion, highlighting the continuing importance of the established treatment franchise.
The company raised its full-year product sales guidance to between $31.0 billion and $31.3 billion. However, its reported earnings outlook also reflects substantial acquisition-related research and development charges. The financial picture therefore combines strong underlying sales with significant expenditure on portfolio expansion.
Gilead shares closed at $170.68 on October 30, 2026, increasing 3.06% during the session after advancing 4.03% on October 29. The gains followed publication of the company’s quarterly results and stronger sales outlook. Because the Glasgow presentation announcement was released on November 2, the earlier share-price movements cannot be attributed to that announcement.
A longer-term commercial challenge involves pricing pressure on Biktarvy. Gilead has disclosed that Medicare pricing changes are expected to reduce its realised price for the medicine beginning in 2028, creating a potential revenue headwind. New HIV products may help diversify the franchise, but their ability to offset future pricing pressure will depend on adoption and the applicable competitive environment.
The HIV Glasgow programme therefore has strategic significance beyond its scientific presentations. It demonstrates the range of development programmes Gilead is pursuing while its existing business generates substantial revenue. The commercial opportunity will depend on converting investigational regimens into approved, accessible treatments without undermining the performance of established products.
What will determine whether Gilead’s long-acting HIV portfolio transforms clinical practice?
The first requirement is reliable efficacy across different patient populations. The ISLEND trials have already demonstrated non-inferiority at week 48, but additional subgroup and longer-term evidence will be important for understanding where once-weekly therapy fits. Regulatory review will determine whether the investigational combination can enter routine clinical use.
For prevention, persistence and access will be central. PURPOSE 5 may provide useful information about whether twice-yearly lenacapavir is more acceptable than daily oral PrEP among individuals who have not previously used established options. However, the full results must be evaluated before drawing conclusions about the programme’s effectiveness in improving real-world protection.
The twice-yearly injectable treatment strategy remains at an earlier stage. GS-3242 and lenacapavir must demonstrate sufficient antiviral coverage, acceptable safety and resistance management over extended dosing intervals. Success cannot be inferred from the approval of lenacapavir for other indications.
Finally, implementation will determine whether treatment convenience becomes a meaningful clinical advantage. Patients may prefer different regimens depending on their circumstances, and healthcare systems must provide the monitoring and support required for sustained viral suppression.
Gilead’s HIV Glasgow 2026 programme reflects a transition from one dominant model of daily oral treatment towards multiple treatment and prevention options with different dosing schedules. Its approved medicines provide a strong commercial foundation, while the investigational pipeline could expand patient choice. The decisive question is whether clinical efficacy, patient preference and healthcare access can align to deliver benefits beyond the convenience of taking fewer doses.
